Last Updated : Aug 13, 2019 01:07 PM IST | Source:

Hold Divi's Laboratories; target of Rs 1640: ICICI Direct

ICICI Direct recommended hold rating on Divi's Laboratories with a target price of Rs 1640 in its research report dated August 12, 2019.

Broker Research
  • bselive
  • nselive
Todays L/H

ICICI Direct's research report on Divi's Laboratories

Q1FY20 revenues grew 16.8% YoY to Rs 1162.9 crore (I-direct estimate: Rs 1318.4 crore), driven by strong growth in generic segment. EBITDA margins fell 206 bps to 33.3% (I-direct estimate of 36.8%) mainly due to higher other expenditure. EBITDA grew 10% YoY to Rs 387.1 crore (I-direct estimate: Rs 484.5 crore). Net profit grew 2.4% to Rs 272.4 crore (I-direct estimate: Rs 350.2 crore) mainly due to a below expected operational performance.


Margins are also likely to get support from extensive backward integration, product mix and operating leverage. We ascribe a target price of Rs 1640 based on 26x FY21E EPS of Rs 63.1.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

First Published on Aug 13, 2019 01:07 pm